The bacterial cell division cycle recently gained attention as a promising target to fight antibiotic resistance. Inhibitors of FtsZ, the highly conserved bacterial protein, main player of this process, are expected to represent a new potential family of antibiotics, characterized by broad-spectrum activity, low cytotoxicity, and the ability to bypass the actual mechanisms of antibiotic-resistance. The benzodioxane-benzamide class of FtsZ inhibitors was deeply developed over the last decade, obtaining potent compounds, including a 2,6-difluorobenzamide moiety, as PC190723. We recently developed some potent derivatives, as antibacterial towards different bacterial strains. However, these are characterized by a quite high lipophilicity, which could limit their water solubility and their absorption. Thus, we aimed at the introduction of a hydroxyl group, as an anchor point to prepare appropriate prodrugs or fluorescent probes. Moreover, we aimed at also including a methyl, in place of the hydroxyl, as a control. Considering the structural modifications performed on PC190723 by Stokes and colleagues, we designed, synthesized, isolated and characterized the single treo and erythro isomers of compounds 1-3. These compounds were evaluated for their antimicrobial activity against methicillin-sensitive, methicillin-resistant, and multidrug-resistant S. aureus, as well as towards different strains of E. coli, determining their MICs. Subsequently, by using fluorescence anisotropy, we validated FtsZ as the target of these derivatives and verified their effect over the dynamics of FtsZ protofilaments.

Design, synthesis and antimicrobial evaluation of benzodioxane-benzamides FtsZ inhibitors: modification of the linker between the two scaffolds / L. Suigo, V. Straniero, G. Lodigiani, C. Zanotto, M. Sobrinos-Sanguino, B. Monterroso, S. Zorrilla, G. Rivas, E. Valoti. ((Intervento presentato al 41. convegno European School of Medicinal Chemistry : July, 3rd - 7th tenutosi a Urbino nel 2022.

Design, synthesis and antimicrobial evaluation of benzodioxane-benzamides FtsZ inhibitors: modification of the linker between the two scaffolds

L. Suigo
Primo
;
V. Straniero
Secondo
;
G. Lodigiani;C. Zanotto;E. Valoti
Ultimo
2022

Abstract

The bacterial cell division cycle recently gained attention as a promising target to fight antibiotic resistance. Inhibitors of FtsZ, the highly conserved bacterial protein, main player of this process, are expected to represent a new potential family of antibiotics, characterized by broad-spectrum activity, low cytotoxicity, and the ability to bypass the actual mechanisms of antibiotic-resistance. The benzodioxane-benzamide class of FtsZ inhibitors was deeply developed over the last decade, obtaining potent compounds, including a 2,6-difluorobenzamide moiety, as PC190723. We recently developed some potent derivatives, as antibacterial towards different bacterial strains. However, these are characterized by a quite high lipophilicity, which could limit their water solubility and their absorption. Thus, we aimed at the introduction of a hydroxyl group, as an anchor point to prepare appropriate prodrugs or fluorescent probes. Moreover, we aimed at also including a methyl, in place of the hydroxyl, as a control. Considering the structural modifications performed on PC190723 by Stokes and colleagues, we designed, synthesized, isolated and characterized the single treo and erythro isomers of compounds 1-3. These compounds were evaluated for their antimicrobial activity against methicillin-sensitive, methicillin-resistant, and multidrug-resistant S. aureus, as well as towards different strains of E. coli, determining their MICs. Subsequently, by using fluorescence anisotropy, we validated FtsZ as the target of these derivatives and verified their effect over the dynamics of FtsZ protofilaments.
Settore CHIM/08 - Chimica Farmaceutica
https://www.soc.chim.it/it/node/2783
Design, synthesis and antimicrobial evaluation of benzodioxane-benzamides FtsZ inhibitors: modification of the linker between the two scaffolds / L. Suigo, V. Straniero, G. Lodigiani, C. Zanotto, M. Sobrinos-Sanguino, B. Monterroso, S. Zorrilla, G. Rivas, E. Valoti. ((Intervento presentato al 41. convegno European School of Medicinal Chemistry : July, 3rd - 7th tenutosi a Urbino nel 2022.
Conference Object
File in questo prodotto:
File Dimensione Formato  
Poster_ESMEC2022_LorenzoSuigo.pptx

accesso aperto

Tipologia: Altro
Dimensione 326.63 kB
Formato Microsoft Powerpoint XML
326.63 kB Microsoft Powerpoint XML Visualizza/Apri
Poster_ESMEC2022_LorenzoSuigo.pdf

accesso aperto

Tipologia: Altro
Dimensione 627.3 kB
Formato Adobe PDF
627.3 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/951581
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact